Patrick Donnelly
Stock Analyst at Citigroup
(3.75)
# 744
Out of 5,120 analysts
361
Total ratings
52.82%
Success rate
7.16%
Average return
Main Sectors:
Stocks Rated by Patrick Donnelly
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TMO Thermo Fisher Scientific | Maintains: Buy | $660 → $685 | $581.77 | +17.74% | 22 | Jan 30, 2026 | |
| CRL Charles River Laboratories International | Maintains: Buy | $200 → $265 | $213.22 | +24.28% | 22 | Jan 16, 2026 | |
| BRKR Bruker | Maintains: Neutral | $40 → $53 | $43.75 | +21.14% | 18 | Jan 16, 2026 | |
| MDLN Medline | Initiates: Buy | $48 | $45.02 | +6.62% | 1 | Jan 12, 2026 | |
| NTRA Natera | Initiates: Buy | $300 | $231.10 | +29.81% | 1 | Jan 7, 2026 | |
| GH Guardant Health | Maintains: Buy | $100 → $135 | $114.90 | +17.49% | 11 | Dec 11, 2025 | |
| TXG 10x Genomics | Downgrades: Neutral | $18 | $19.95 | -9.77% | 13 | Dec 11, 2025 | |
| QGEN Qiagen | Downgrades: Neutral | $52 → $48 | $52.18 | -8.74% | 14 | Dec 11, 2025 | |
| FTRE Fortrea Holdings | Upgrades: Buy | $12 → $21 | $16.86 | +24.56% | 5 | Dec 11, 2025 | |
| A Agilent Technologies | Maintains: Buy | $165 → $185 | $135.39 | +36.64% | 27 | Nov 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,600 → $1,700 | $1,385.61 | +22.69% | 15 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $350 → $375 | $297.43 | +26.08% | 17 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $350 → $375 | $295.05 | +27.10% | 17 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $200 → $230 | $231.23 | -0.53% | 13 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $40 → $33 | $27.65 | +19.35% | 6 | Oct 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $225 → $200 | $178.59 | +11.99% | 10 | Aug 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $55 → $70 | $65.25 | +7.28% | 12 | Aug 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $42 | $23.32 | +80.10% | 2 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $60 → $80 | $74.74 | +7.04% | 15 | Jul 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $85 → $80 | $141.13 | -43.31% | 17 | Jul 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $22 → $18 | $11.07 | +62.60% | 8 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $185 | $185.00 | - | 11 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $285 → $265 | $223.42 | +18.61% | 12 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $20 | $18.30 | +9.29% | 3 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $75 | $102.50 | -26.83% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $28 | $15.73 | +78.00% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $135 → $145 | $107.09 | +35.40% | 1 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $265 → $300 | $379.31 | -20.91% | 24 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $9 | $2.92 | +208.22% | 6 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3.75 → $2.75 | $2.79 | -1.43% | 4 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $250 → $260 | $270.29 | -3.81% | 11 | Feb 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $6 | $9.35 | -35.83% | 4 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $28 → $32 | $5.47 | +485.01% | 2 | Nov 30, 2018 |
Thermo Fisher Scientific
Jan 30, 2026
Maintains: Buy
Price Target: $660 → $685
Current: $581.77
Upside: +17.74%
Charles River Laboratories International
Jan 16, 2026
Maintains: Buy
Price Target: $200 → $265
Current: $213.22
Upside: +24.28%
Bruker
Jan 16, 2026
Maintains: Neutral
Price Target: $40 → $53
Current: $43.75
Upside: +21.14%
Medline
Jan 12, 2026
Initiates: Buy
Price Target: $48
Current: $45.02
Upside: +6.62%
Natera
Jan 7, 2026
Initiates: Buy
Price Target: $300
Current: $231.10
Upside: +29.81%
Guardant Health
Dec 11, 2025
Maintains: Buy
Price Target: $100 → $135
Current: $114.90
Upside: +17.49%
10x Genomics
Dec 11, 2025
Downgrades: Neutral
Price Target: $18
Current: $19.95
Upside: -9.77%
Qiagen
Dec 11, 2025
Downgrades: Neutral
Price Target: $52 → $48
Current: $52.18
Upside: -8.74%
Fortrea Holdings
Dec 11, 2025
Upgrades: Buy
Price Target: $12 → $21
Current: $16.86
Upside: +24.56%
Agilent Technologies
Nov 25, 2025
Maintains: Buy
Price Target: $165 → $185
Current: $135.39
Upside: +36.64%
Nov 10, 2025
Maintains: Buy
Price Target: $1,600 → $1,700
Current: $1,385.61
Upside: +22.69%
Oct 30, 2025
Maintains: Buy
Price Target: $350 → $375
Current: $297.43
Upside: +26.08%
Oct 30, 2025
Maintains: Buy
Price Target: $350 → $375
Current: $295.05
Upside: +27.10%
Oct 29, 2025
Maintains: Neutral
Price Target: $200 → $230
Current: $231.23
Upside: -0.53%
Oct 7, 2025
Downgrades: Neutral
Price Target: $40 → $33
Current: $27.65
Upside: +19.35%
Aug 21, 2025
Downgrades: Neutral
Price Target: $225 → $200
Current: $178.59
Upside: +11.99%
Aug 21, 2025
Upgrades: Buy
Price Target: $55 → $70
Current: $65.25
Upside: +7.28%
Aug 13, 2025
Maintains: Buy
Price Target: $34 → $42
Current: $23.32
Upside: +80.10%
Jul 9, 2025
Upgrades: Buy
Price Target: $60 → $80
Current: $74.74
Upside: +7.04%
Jul 9, 2025
Downgrades: Sell
Price Target: $85 → $80
Current: $141.13
Upside: -43.31%
Mar 4, 2025
Maintains: Neutral
Price Target: $22 → $18
Current: $11.07
Upside: +62.60%
Mar 4, 2025
Downgrades: Neutral
Price Target: $185
Current: $185.00
Upside: -
Jan 30, 2025
Maintains: Buy
Price Target: $285 → $265
Current: $223.42
Upside: +18.61%
Nov 6, 2024
Maintains: Buy
Price Target: $18 → $20
Current: $18.30
Upside: +9.29%
Nov 6, 2024
Maintains: Buy
Price Target: $80 → $75
Current: $102.50
Upside: -26.83%
Aug 7, 2024
Maintains: Buy
Price Target: $30 → $28
Current: $15.73
Upside: +78.00%
Jul 30, 2024
Maintains: Buy
Price Target: $135 → $145
Current: $107.09
Upside: +35.40%
Dec 11, 2023
Maintains: Neutral
Price Target: $265 → $300
Current: $379.31
Upside: -20.91%
Dec 11, 2023
Maintains: Buy
Price Target: $7 → $9
Current: $2.92
Upside: +208.22%
Aug 10, 2023
Maintains: Neutral
Price Target: $3.75 → $2.75
Current: $2.79
Upside: -1.43%
Feb 17, 2023
Maintains: Neutral
Price Target: $250 → $260
Current: $270.29
Upside: -3.81%
Nov 3, 2022
Maintains: Buy
Price Target: $8 → $6
Current: $9.35
Upside: -35.83%
Nov 30, 2018
Upgrades: Neutral
Price Target: $28 → $32
Current: $5.47
Upside: +485.01%